{"id":"olumacostat-glasaretil-gel-5-0","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Dryness"}]},"_chembl":{"chemblId":"CHEMBL3989947","moleculeType":"Small molecule","molecularWeight":"481.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug is a topical SOAT1 inhibitor that decreases sebaceous gland lipid synthesis and sebum secretion. By reducing sebum production, it addresses the underlying pathophysiology of acne and other sebum-related skin conditions. This mechanism targets a key driver of acne pathogenesis without systemic absorption.","oneSentence":"Olumacostat glasaretil inhibits sebum production by blocking sterol O-acyltransferase (SOAT1), reducing lipid accumulation in sebaceous glands.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:06.529Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"}]},"trialDetails":[{"nctId":"NCT03073486","phase":"PHASE3","title":"A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Dermira, Inc.","startDate":"2017-02-06","conditions":"Acne Vulgaris","enrollment":744},{"nctId":"NCT03028363","phase":"PHASE3","title":"A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Dermira, Inc.","startDate":"2016-12-27","conditions":"Acne Vulgaris","enrollment":759},{"nctId":"NCT03127956","phase":"PHASE3","title":"A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Dermira, Inc.","startDate":"2017-03-21","conditions":"Acne Vulgaris","enrollment":748}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DRM01","DRM01B"],"phase":"phase_3","status":"active","brandName":"Olumacostat Glasaretil Gel, 5.0%","genericName":"Olumacostat Glasaretil Gel, 5.0%","companyName":"Dermira, Inc.","companyId":"dermira-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olumacostat glasaretil inhibits sebum production by blocking sterol O-acyltransferase (SOAT1), reducing lipid accumulation in sebaceous glands. Used for Acne vulgaris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}